These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1354673)

  • 1. Radioimmunoassay for the synthetic ergoline derivative cabergoline in biological fluids.
    Persiani S; Pianezzola E; Broutin F; Fonte G; Strolin Benedetti M
    J Immunoassay; 1992; 13(3):457-76. PubMed ID: 1354673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunoassay for the testosterone 5 alpha-reductase inhibitor turosteride in biological fluids.
    Persiani S; Broutin F; Pianezzola E; Panzeri A; Fonte G; Fontana E; Strolin Benedetti M
    J Immunoassay; 1994 May; 15(2):97-113. PubMed ID: 8040353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectrophotometric determination of dopaminergic drugs used for Parkinson's disease, cabergoline and ropinirole, in pharmaceutical preparations.
    Onal A; Cağlar S
    Chem Pharm Bull (Tokyo); 2007 Apr; 55(4):629-31. PubMed ID: 17409559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of cabergoline in plasma and urine by high-performance liquid chromatography with electrochemical detection.
    Pianezzola E; Bellotti V; La Croix R; Strolin Benedetti M
    J Chromatogr; 1992 Feb; 574(1):170-4. PubMed ID: 1352782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of cabergoline.
    Del Dotto P; Bonuccelli U
    Clin Pharmacokinet; 2003; 42(7):633-45. PubMed ID: 12844325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
    Frans E; Dom R; Demedts M
    Eur Respir J; 1992 Feb; 5(2):263-5. PubMed ID: 1348483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunoassay of nicergoline in biological material.
    Bizollon CA; Rocher JP; Chevalier P
    Eur J Nucl Med; 1982; 7(7):318-21. PubMed ID: 7117274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabergoline : a review of its use in the treatment of Parkinson's disease.
    Curran MP; Perry CM
    Drugs; 2004; 64(18):2125-41. PubMed ID: 15341508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers.
    Persiani S; Rocchetti M; Pacciarini MA; Holt B; Toon S; Strolin-Benedetti M
    Biopharm Drug Dispos; 1996 Jul; 17(5):443-55. PubMed ID: 8830979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson's disease.
    Jori MC; Franceschi M; Giusti MC; Canal N; Piolti R; Frattola L; Bassi S; Calloni E; Mamoli A; Camerlingo M
    Adv Neurol; 1990; 53():539-43. PubMed ID: 2239494
    [No Abstract]   [Full Text] [Related]  

  • 12. Beneficial effect of cabergoline, new long-lasting D2 agonist in the treatment of Parkinson's disease.
    Rabey JM; Nissipeanu P; Inzelberg R; Korczyn AD
    Clin Neuropharmacol; 1994 Jun; 17(3):286-93. PubMed ID: 9316674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitive, specific radioimmunoassay for quantifying pergolide in plasma.
    Bowsher RR; Apathy JM; Compton JA; Wolen RL; Carlson KH; DeSante KA
    Clin Chem; 1992 Oct; 38(10):1975-80. PubMed ID: 1394981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease.
    Navan P; Bain PG
    J Neurol Neurosurg Psychiatry; 2002 Nov; 73(5):602-3. PubMed ID: 12397168
    [No Abstract]   [Full Text] [Related]  

  • 15. Controlled study of the antiparkinsonian activity and tolerability of cabergoline.
    Hutton JT; Morris JL; Brewer MA
    Neurology; 1993 Mar; 43(3 Pt 1):613-6. PubMed ID: 8451010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabergoline: a long-acting dopamine agonist in Parkinson's disease.
    Lera G; Vaamonde J; Muruzabal J; Obeso JA
    Ann Neurol; 1990 Oct; 28(4):593-4. PubMed ID: 2252377
    [No Abstract]   [Full Text] [Related]  

  • 17. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group.
    Webster J; Piscitelli G; Polli A; D'Alberton A; Falsetti L; Ferrari C; Fioretti P; Giordano G; L'Hermite M; Ciccarelli E
    Clin Endocrinol (Oxf); 1993 Sep; 39(3):323-9. PubMed ID: 7900937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.
    Hutton JT; Koller WC; Ahlskog JE; Pahwa R; Hurtig HI; Stern MB; Hiner BC; Lieberman A; Pfeiffer RF; Rodnitzky RL; Waters CH; Muenter MD; Adler CH; Morris JL
    Neurology; 1996 Apr; 46(4):1062-5. PubMed ID: 8780092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients.
    Ferrari C; Paracchi A; Romano C; Gerevini G; Boghen M; Barreca A; Fortini P; Dubini A
    Clin Endocrinol (Oxf); 1988 Nov; 29(5):467-76. PubMed ID: 2908102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabergoline in Parkinson's disease: long-term follow-up.
    Lera G; Vaamonde J; Rodriguez M; Obeso JA
    Neurology; 1993 Dec; 43(12):2587-90. PubMed ID: 7902970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.